- Home
- ULY vs BTAI Comparison
ULY vs BTAI Comparison
Compare ULY & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- BTAI
- Stock Information
- Founded
- ULY 2013
- BTAI 2017
- Country
- ULY United States
- BTAI United States
- Employees
- ULY N/A
- BTAI N/A
- Industry
- ULY
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ULY
- BTAI Health Care
- Exchange
- ULY Nasdaq
- BTAI Nasdaq
- Market Cap
- ULY 7.1M
- BTAI 8.3M
- IPO Year
- ULY N/A
- BTAI 2018
- Fundamental
- Price
- ULY $5.13
- BTAI $5.48
- Analyst Decision
- ULY Strong Buy
- BTAI Strong Buy
- Analyst Count
- ULY 2
- BTAI 4
- Target Price
- ULY $11.50
- BTAI $40.00
- AVG Volume (30 Days)
- ULY 28.4K
- BTAI 22.4M
- Earning Date
- ULY 08-12-2025
- BTAI 08-12-2025
- Dividend Yield
- ULY N/A
- BTAI N/A
- EPS Growth
- ULY N/A
- BTAI N/A
- EPS
- ULY N/A
- BTAI N/A
- Revenue
- ULY $131,235,000.00
- BTAI $868,000.00
- Revenue This Year
- ULY N/A
- BTAI N/A
- Revenue Next Year
- ULY $21.54
- BTAI $328.13
- P/E Ratio
- ULY N/A
- BTAI N/A
- Revenue Growth
- ULY N/A
- BTAI N/A
- 52 Week Low
- ULY $2.99
- BTAI $1.17
- 52 Week High
- ULY $17.99
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- ULY 43.88
- BTAI 67.45
- Support Level
- ULY $4.77
- BTAI $1.30
- Resistance Level
- ULY $5.74
- BTAI $8.08
- Average True Range (ATR)
- ULY 0.50
- BTAI 1.23
- MACD
- ULY 0.03
- BTAI 0.33
- Stochastic Oscillator
- ULY 59.06
- BTAI 61.65
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.